CAMPI DI INTERESSE
PATOLOGIE PROSTATICHE
ONCOLOGIA UROLOGICA
PUBBLICAZIONI SCIENTIFICHE SELEZIONATE
Alessandro Sciarra
Numero massimo 30+5 (trenta + cinque)
Impact Factor (IF) 2005: Totale = 104,753 Media=2.99
F.Di Silverio, G.D`Eramo, G.P.Flammia, M.Caponera, D.Macri`, A.Loreto, A.Sciarra
New Ultrasensitive assay development by using monoclonal antibodies for detecting prostate specific antigen.
European Urology. 21,suppl.1,79-82,1992.
Monaco ISSN 03202-2838
IF= 3.542
F.DiSilverio,G.D`Eramo,C.Lubrano,G.P.Flammia,A.Sciarra,E.Palma, M.Caponera, F.Sciarra.
Evidence that serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients.
European. Urology .21 ,309-314, 1992.
Monaco ISSN 0302-2838
IF=3.542
Di Silverio F.,D`Eramo G.,Buscarini M.,Sciarra A.,Casale P.Loreto A., Di Nicola S., Seccareccia F.,De Vita R.
DNA ploidy,Gleason score,Pathological stage and serum PSA levels as predictors of disease free survival in C-D1 prostate cancer patients submitted to radical retropubic prostatectomy.
European. Urology. 30,3,316-321,1996.
Monaco ISSN 0302-2838
IF=3.542
A.Sciarra,G.DEramo,P.Casale,S.Di Nicola,A.Loreto,M.Buscarini,F Seccareccia e F. Di Silverio.
Relationship among symptom score, prostate volume and urinary flow rate in 543 men with and without benign prostatic hyperplasia.
The Prostate 34:121-128;1998
New York ISSN 0270-4137
IF=3.602
F.Di Silverio,A.Sciarra, G.DEramo,P.Casale,A.Loreto,F.Seccareccia.
Relationship among age,prostate specific antigen and prostate volume in men with LUTS and in different groups of men with and without benign and malignant prostate diseases.
The Prostate ;36:1-7;1998
New York ISSN 0270-4137
IF=3.602
F.DiSilverio,S.Monti, A.Sciarra,PA Varasano C.Martini,S.Lanzana,G.DEramo,S.Di Nicola, V.Toscano.Effects of long term treatment with serenoa repens on the concentrations and regional distribution of androgen and epidermal growth factor in benign prostatic hyperplasia.
The Prostate 37:77-83;1998.
New York ISSN 0270-4137
IF=3.602
F.Di Silverio,A.Sciarra, S MontiP.Casale,F.Seccareccia.
Can the intraprostatic concentration of epidermal growth factor influence the variance of serum prostate specific antigen levels in patients with benign prostatic hyperplasia?
Journal Urology. 161(1):128-32; 1999.
Baltimore ISSN 0022-5347
IF=3.592
F.Di Silverio,P.Casale,D.Colella,A.Loreto,F.Seccareccia,A.Sciarra.
Independent value of tumor size and DNA ploidy for the prediction of disease
Progression in patients with organ confined Renal Cell Carcinoma.
Cancer 88(4):835-45;2000.
New York ISSN 0008-543X
IF=4.80
A.Sciarra,C Bosman,O.Schillaci,M MontiC.Di Chiro e F.Di Silverio.
Clinical evidence of neuroendocrine differentiation in a patient with prostate cancer and Bone marrow micrometastases.
British.Journal.Urology. 87:123-5;2001.
Oxford ISSN 1464-4096
IF=2.247
A Sciarra,G Voria, A Pastore, G Mariotti F Di Silverio .Histopathological aspects associated with the diagnosis of benign prostatic hyperplasia:clinical implications.
Urologia Internationalis 69;253-262; 2002
ISSN 0042-1138
IF=0.585
A. Sciarra,G. Voria, A.Loreto, F. Seccareccia, F Di Silverio. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10.
Urologia Internationalis. 2003; 70(3): 186-94.
ISSN 0042-1138
IF=0.585
A Sciarra, G Mariotti,V.Gentile,G Voria, A Pastore, S Monti, F Di Silverio. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? (Review article)
British Journal Urology 2003;91:438-445
Oxford ISSN 1464-4096
IF=2.247
A.Sciarra, S. Monti, V Gentile, G Mariotti, A. Cradi, R Lucera, F Di Silverio.
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Prostate. 2003 May 15; 55(3): 168-79.
New York ISSN 0270-4137
IF=3.602
F. Di Silverio,V Gentile, A. De Matteis,G Mariotti,G. Voria, A Pastore, A. Sciarra.
Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.
European Urology. 2003 Feb; 43(2): 164-75.
Monaco ISSN 0302-2838
IF=3.542
F Di Silverio,A Sciarra. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Journal of Urology. 2003 Nov; 170(5): 1812-6.
Baltimore ISSN 0022-5347
IF=3.592
A.Sciarra, G. Voria, S. Monti,L.Mazzone,G. Mariotti,M. Pozza, G. DEramo,F Di Silverio. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
Prostate 2004;58:421-428
New York ISSN 0270-4137
IF=3.602
A. Sciarra, F. Di Silverio. Effect of non-steroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Urology 2004 ;63(3) 523-527
New York ISSN 0090-4295
IF=2.139
A. Sciarra,,V.Gentile,G.Mariotti, G. Voria, A. De Matteis, F Di Silverio. Histopathological aspects of transitional cell carcinoma of the bladder:analysis on 20 years of experience.
International Journal Urolology. 2004 11(7):467-475
ISSN 0919-872
IF=0.529
A. Sciarra,C. Bosman, S. Monti,V Gentile, M Ciccariello, A. Pastore,G Salvatori, F fattore, F Di Silverio.Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate carcinoma.
Journal Urology. 2004 Nov;172(5 Pt 1):1775-83.
Baltimore ISSN 0022-5347
IF=3.592
Cerulli C,A. Sciarra,G salvatori, F Di Silverio. Long term response to the combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Urology 2004 ;64(6):1231-1233
New York ISSN 0090-4295
IF=2.139
F Di Silverio,C Bosman,Monti S,L Proietti Pannunzi,M Ciccariello,A Cardi,G Salvatori, A Sciarra.Combination Therapy With Rofecoxib And Finasteride In The Treatment Of Men With Lower Urinary Tract Symptoms (Luts) And Benign Prostatic Hyperplasia (BPH).
European Urology. 2005 Jan;47(1):72-8
Monaco ISSN 0302-2838
IF=3.542
A. Sciarra, S. Monti, V Gentile, S Salciccia, A. Autran Gomez, L. Pannunzi, F Di Silverio.Chromogranin A expression in familial versus sporadic prostate cancer.
Urology 2005; 66(5):1010-1014
New York ISSN 0090-4295
IF=2.139
A. Sciarra, S Salciccia,L Albanese,A Cardi,G DEramo, F Di Silverio. Use of cyclooxigenase -2 inhibitors for the prevention of urethral striature secondary to transurethral resection of the prostate.
Urology. 2005 Dec;66(6):1218-22
New York ISSN 0090-4295
IF=2.139
Sciarra A Neuroendocrine differentiation in prostate adenocarcinoma.
European Urology. 2007 Nov;52(5):1373.
Monaco ISSN 0302-2838
IF=3.542
Sciarra A,Di Silverio F, Salciccia S, Autran Gomez A,Gentilucci A, Gentile V.Inflammation and chronic prostatic diseases: evidence for a link?
European Urology. 2007 Oct;52(4):964-72.
Monaco ISSN 0302-2838
IF=3.542
Sciarra A, Autran Gomez A,Gentilucci A,Parente U,Salciccia S, Gentile V, Di Silverio F.Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
European Urology. 2007 Aug;52(2):597-9.
Monaco ISSN 0302-2838
IF=3.542
Sciarra A,Salciccia S.New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?
European Urology. 2007 Oct;52(4):945-7.
Monaco ISSN 0302-2838
IF=3.542
Sciarra A. Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
European Urology. 2007 Jun;51(6):1485-7. Epub 2007 Jan 26.
Monaco ISSN 0302-2838
IF=3.542
Sciarra A, Lichtner M, Autran Gomez A,Nastroianni C, Rossi R, Mengoni F,Cristini C,Gentilucci A, Vullo V, Di Silverio F.Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.
Prostate. 2007 Jan 1;67(1):1-7.
New York ISSN 0270-4137
IF=3.602
Sciarra A,Gentile V, Autran Gomez A,Salciccia S,Gentilucci A,Monti S,Toscano V,Di Silverio F
Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Endocrine Related Cancer. 2007 Sep;14(3):625-32.
ISSN 1479-6821 (E057780)
IF= 4.763
Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Gentilucci A, Lisi D, Passariello R, Gentile V, Di Silverio F. Complete Response to the Combination Therapy with Androgen Blockade and Somatostatin Analogue in a Patient with Advanced Prostate Cancer: Magnetic Resonance Imaging with 1H-Spectroscopy.
European Urology. 2008; 53:652-658
Monaco ISSN 0302-2838
IF=3.542
Sciarra A,Panebianco V,Di Silverio F,Salciccia S,Osimani M,Lisi D,Ciccariello M,Passariello R, Gentile V. Role of dynamic contrast enhanced magnetic resonance imaging and proton MR spectroscopic imaging in thye detection of local recurrence after radicl prostatectomy for prostate cancer.
European Urology 2007 Dec 31. [Epub ahead of print]
PMID: 18226441
Monaco ISSN 0302-2838
IF=3.542
Di Silverio F, Sciarra A, Gentile V. Etoricoxib and intermitent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Urology 2008 Feb 14. [Epub ahead of print]
PMID: 18279940
New York ISSN 0090-4295
IF=2.139
Sciarra A,Gentile V,Monti S,Dattilo C,Autran Gomez A,Salciccia S,Pannunzi L,Toscano V,Di Silverio F. Comparison of chromogranin A, insulin-like growth factor1 and prostate specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urologia Internationalis 2008;80:68-73
ISSN 0042-1138
IF=0.585
Sciarra A,Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V,Di Silverio F.Prostate growth and inflammation.
Journal Steroid Biochemistry Molecular Biology. 2008;108:254-260
ISSN 0960-0760
IF=2.825
